BRI3 Inhibitors
Chemical inhibitors of BRI3 can modulate the protein's activity through diverse mechanisms of action by targeting various signaling pathways in which BRI3 is involved. Wortmannin and LY294002, both phosphoinositide 3-kinase (PI3K) inhibitors, can lead to a reduction in AKT signaling, a pathway upstream of BRI3. The inhibition of PI3K by these compounds can result in decreased AKT activation, which is essential for the phosphorylation and subsequent activation of proteins that are regulated by AKT, including BRI3. Similarly, Dasatinib and PP2 function by selectively inhibiting Src family kinases. The activity of BRI3 can be attenuated when these kinases are inhibited because BRI3 is linked to signaling pathways incorporating Src family kinase activity. Reduced activation of these kinases can lead to a decrease in the functional activity of BRI3, which may rely on Src signaling for its role within the cell.
Further regulating the activity of BRI3, U0126 and PD98059 target the MAPK/ERK pathway by inhibiting MEK1/2. The inhibition of MEK disrupts the phosphorylation and activation of ERK, a kinase that can control the function of BRI3. SB203580 and SP600125 inhibit other MAPK family members, namely p38 MAPK and JNK, respectively. BRI3 activity that depends on signaling through these MAPK pathways can be inhibited when p38 MAPK or JNK activation is blocked. Additionally, GF109203X and Go6983, inhibitors of protein kinase C (PKC), can alter BRI3 activity by impeding PKC-mediated signaling pathways. The inhibition of PKC can therefore lead to a decrease in BRI3 functionality if its activity is regulated by PKC-dependent processes. Lastly, mTOR pathway inhibitors such as Rapamycin and AZD8055 can suppress the functional activity of BRI3 by targeting mTORC1 and mTORC2 complexes. Inhibition of mTOR signaling can affect BRI3 if its activity is interwoven with mTOR-dependent cellular processes.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are upstream regulators of AKT signaling. BRI3 is implicated in pathways that involve AKT signaling. Inhibition of PI3K leads to reduced AKT activation, which in turn can inhibit downstream proteins that rely on AKT-mediated phosphorylation, including BRI3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, functioning similarly to Wortmannin. By inhibiting PI3K, it reduces AKT activation, potentially inhibiting the activity of BRI3, which may rely on AKT signaling for its functional activity within the cell. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. As BRI3 is involved in pathways that include Src family kinase signaling, the inhibition of these kinases can lead to a decreased activation of downstream targets, potentially inhibiting BRI3 activity that is dependent on Src signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src family kinases, PP2 can reduce the activation of downstream proteins that are part of the same signaling pathway as BRI3, potentially leading to functional inhibition of BRI3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key components in the MAPK/ERK pathway. BRI3, associated with this signaling pathway, would experience reduced functional activity due to the inhibition of MEK1/2, which is necessary for the phosphorylation and activation of ERK that can regulate the activity of BRI3. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that inhibits the activation of MAPK/ERK kinase. If BRI3 activity is regulated by the MAPK/ERK pathway, inhibition of MEK by PD98059 can lead to a decrease in ERK-mediated phosphorylation events, thus inhibiting BRI3's functionality in the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK. Given that BRI3 is involved in pathways that include p38 MAPK signaling, the inhibition of p38 MAPK by SB203580 can lead to the functional inhibition of BRI3 by preventing its activation through this specific MAPK cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, part of the MAPK family. BRI3's activity that depends on the JNK signaling pathway would be inhibited due to the blockade of JNK activation, leading to reduced functionality of BRI3 in processes that require JNK-mediated signaling. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is a potent inhibitor of protein kinase C (PKC). If BRI3's activity is modulated via PKC-dependent signaling pathways, the inhibition of PKC by GF109203X could lead to a functional inhibition of BRI3 by preventing its PKC-mediated regulation. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a broad-spectrum PKC inhibitor. By inhibiting PKC, Go6983 can disrupt the signaling pathways that rely on PKC for activation, including those involving BRI3. This disruption can inhibit the functional activity of BRI3 if it depends on PKC-mediated processes within the cell. | ||||||